CALL FOR PROPOSALS 2016

Fellowships for Abroad
TABLE OF CONTENTS

Foreword ......................................................................................................................................................... 3
Eligibility criteria for applicants .......................................................................................................................... 3
The Hosting Institution ......................................................................................................................................... 3
The research plan .............................................................................................................................................. 4
The review process ........................................................................................................................................... 4
Funding ............................................................................................................................................................ 4
Duration ............................................................................................................................................................ 5
Bio-Ethical Requirements ................................................................................................................................. 5
Deadlines ........................................................................................................................................................... 6
Guide to proposal preparation ............................................................................................................................. 7
General information ........................................................................................................................................... 7
Applicant’s personal data .................................................................................................................................. 8
Type of fellowship .............................................................................................................................................. 8
Head of the hosting lab ...................................................................................................................................... 8
Legal representative .......................................................................................................................................... 8
Head of the laboratory of origin ......................................................................................................................... 8
Education and training of the applicant ............................................................................................................. 8
Research and professional experience of the applicant ..................................................................................... 8
Research interruptions and justifications ........................................................................................................... 9
Curriculum vitae of the applicant ....................................................................................................................... 9
Narrative biosketch .......................................................................................................................................... 9
Certificate of graduation .................................................................................................................................... 9
Publications of the applicant ............................................................................................................................. 9
Project keywords .............................................................................................................................................. 11
Research project .............................................................................................................................................. 11
Letter of acceptance by the Hosting Institution ............................................................................................... 12
Education and training of the head of the hosting lab ....................................................................................... 12
Research and professional experience of the head of the hosting lab ............................................................... 12
Publications of the head of the hosting lab ......................................................................................................... 12
Bio-Ethical Requirements ................................................................................................................................. 12
Financial support .............................................................................................................................................. 12
Proposal PDF Draft .......................................................................................................................................... 15
Final Full Proposal Submission ........................................................................................................................ 15
Template - Agreement for the provision of fellowship awards funded by Fondazione Italiana per la Ricerca sul Cancro - AIRC .................................................................................................................. 17

Keywords ........................................................................................................................................................ 20

Foreword
The Fondazione Italiana per la Ricerca sul Cancro – AIRC henceforth referred as Foundation will award one-year Fellowships in cancer research to highly qualified young graduates and/or post-doctoral fellows or equivalent who wish to broaden or acquire experience in oncological research, in a cancer-focused laboratory outside of Italy.

Eligibility criteria for applicants
At the time of the deadline for submission, the following eligibility criteria must be met:

• applicants must have a degree in Medicine, Biological Sciences, Pharmacy, Chemistry and Pharmaceutical Technology, Medical Statistics, Medical Biotechnologies or other scientific disciplines, provided that the focus of the proposed research plan in the application is cancer;
• the degree must be an Italian laurea magistralis, i.e. 5-6 years of undergraduate degree, or an equivalent non Italian degree (candidates who only have a “laurea breve” are not eligible), and it must have been attained after December 31, 2009; exceptions are allowed only in case of research interruptions due to parental leave, children care, illness;
• the institution of origin must be located in Italy: applicants who are already working abroad cannot apply;
• candidates who have already been awarded a Fellowship under this funding scheme and/or an Outgoing Fellowship cofounded by AIRC and Marie Curie Actions cannot apply;
• a maximum of two candidates with the same head of the lab of origin can apply;
• a maximum of two candidates with the same head of the Hosting lab can apply.

Please make sure that all eligibility requirements indicated are met. Applications from researchers who do not meet the eligibility criteria will not be sent out for review and will automatically be rejected.

The Hosting Institution
For the entire duration of the fellowships applicants must operate in the Hosting Institution, i.e. a research organization (such as university, hospital or other research center), irrespective of its legal status (organized under public or private law), whose primary goal is to independently conduct non-economic biomedical research and to disseminate its results. Possible revenues coming from non-economic research activity must be completely reinvested in the non-economic research activities. Where the Hosting Institution also pursues economic activities, the financing, the costs and the revenues of those economic activities must be accounted for separately. Shareholders, members or other individuals that can exert a decisive influence upon the Hosting Institution cannot enjoy a preferential access to the intellectual property of the results generated by the non-economic research activity. Any change occurring in the relationship between the fellow and the Hosting Institution (e.g. termination, leave of absence, etc.) or in the Hosting Institution legal entity or organization (e.g. changes in Institution name, merging, Legal representative turn-over, changes in addresses) must be promptly notified to the Foundation.
Hosting Institutions must assure optimal working conditions to the fellows: in addition to providing facilities, equipment, and infrastructure, the Hosting Institution, and especially the head of the hosting lab, are expected to offer adequate training resources and cover expenses to travel to conferences and meetings when they are deemed important for the training and education of the fellow.
A letter of acceptance of the applicant by the head of the hosting lab must be included in the application, describing all resources and training opportunities available. The head of the hosting lab is expected to supervise the work of the fellow, and provide training and mentoring.
The research plan
Applications must include a detailed research plan, agreed with the head of the hosting lab, with a clear focus on cancer. The same research project cannot be presented by two or more applicants within the 2016 Calls.

The review process
All applications undergo an initial administrative review by the staff of the Peer Review Office for compliance with guidelines and eligibility; those that do not conform will be triaged out. Applications that meet the eligibility requirements undergo a peer review process that ensures a fair, independent and expert evaluation of their scientific merit and competitiveness. All applications will be evaluated by recognized Italian scientists members of the Comitato Tecnico Scientifico (CTS) and a panel of about 600 well-established international investigators working in institutions outside of Italy. Applications are independently evaluated by two members of the CTS and one international reviewer. Reviewer assignments are made in compliance with conflict of interest rules to ensure a review free from inappropriate influence. The policy on Conflict of Interest is available here: https://www.direzionescientifica.airc.it/Policies/Default.aspx
When accepting to evaluate an application, reviewers agree that they will maintain the confidentiality of the application and associated materials they have received.

The following review criteria will be used to evaluate applications:

- **Quality of the Hosting laboratory and Institution**
  Reviewers will evaluate the quality of the Hosting Institution (laboratories, facilities, training potential also in complementary skills) as well as the competence of the head of the hosting laboratory (in terms of expertise in the field, track record, international standing and ability to provide mentoring).

- **Curriculum vitae of the applicant**
  Reviewers will evaluate the applicant’s education/transcripts, track record and expertise.

- **Research proposal**
  The research project will be judged based on its relevance to cancer, innovation, feasibility, and overall scientific/technological quality.

When all evaluations have been submitted, reviewers are invited to read the critiques of the other two reviewers who evaluated the same proposals and make additional comments, if needed. For each application, the scores received from all reviewers will be averaged to generate the application’s global score, which will be used to rank the applications. The selection will be exclusively based on this ranking. The budget available to the Foundation for all the fellowships in this Call is € 250,000.00. In case the applications considered meritorious of funding exceed this budget, the Associazione Italiana per la Ricerca sul Cancro (AIRC) reserves the rights to increase the number of fellowships to be awarded, provided that funds are available. At the end of the review process, on the date indicated in the Deadlines table, all candidates will be notified of the result of their application with a communication from the Foundation that will include the anonymous reviewers’ comments. The decision cannot be appealed.

Funding
Financial support must be requested through the specific section of the online form. The financial support provided comprises:
- **living allowance**: it is the fellowship gross amount, it should be calculated according to the standard costs of living where the Hosting Institution is located and shall not exceed the standard salary of a fellow at the same career level working in the same Institution. In any case, a budget limit has been set depending on the Country where the Hosting Institution is located: please be sure that the requested amount does not exceed it. Please see Annex A for details.
- **travel expenses**: please indicate the cost expected for one roundtrip ticket to the city where the Hosting Institution is located. Travel must be in economy class and with the lowest fare possible. Travel expenses will be directly reimbursed upon presentation of the ticket receipt;
- **health insurance**: health insurance costs may be reimbursed by the Foundation upon presentation of supporting documentation, in case the Country or the Hosting Institution do not cover these expenses. In this case, please indicate in this section of the application form an estimate or quotation of these costs.

The Living allowance will be transferred by the Foundation to the Hosting Institution, after a specific agreement between the two parties is set up (a template of the Agreement is included in this Call), and will be used by the Hosting Institution to pay the fellow’s salary monthly in local currency, applying the local contributions and taxes. At the end of the fellowship appointment, Hosting Institutions will be requested to provide a financial reconciliation statement. In case such an agreement is not set up, the Foundation will pay in Euros the fellow’s living allowance directly, deducting the taxes according to the Italian regulations. **The amount remaining from the living allowance, after taxes have been paid, is the fellow’s net salary.**

The amount granted is intended to cover the salary of the fellow only: deductions by the Hosting Institution for indirect costs or overheads are not allowed.

**Duration**

Fellowships will have a duration of one year; they should start anytime between January 1st 2017 and June 1st 2017, and will not be renewable. At the end of the funding period, a final scientific report will be required.

**Bio-Ethical Requirements**

For studies involving human subjects, human biological samples or for animal experimentation, the approval of the competent authorities is mandatory and must be submitted with the full application. The fellowship will not be awarded in the absence of the necessary authorizations. If the approval from the competent authorities is not available by the submission deadline, the applicant must obtain it by November 15th 2016, if possible, or in any case before the fellowship starts. Please upload it as PDF file in the “Personal Area” or send it to the Peer Review Office by e-mail (airc.direzione-scientifica@airc.it).
Deadlines

Deadlines are strictly enforced: applications will not be accepted beyond the relevant deadlines.

Deadlines for applications (by 5 PM, Central European Time, of the indicated dates)

<table>
<thead>
<tr>
<th>Applications</th>
<th>publication of call and release of online application forms</th>
<th>May 17, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>electronic submission deadline</td>
<td>June 27, 2016</td>
</tr>
<tr>
<td></td>
<td>paper submission (postmark) deadline (*)</td>
<td>July 7, 2016</td>
</tr>
<tr>
<td></td>
<td>notification of results</td>
<td>November 30, 2016</td>
</tr>
<tr>
<td></td>
<td>start of fellowship</td>
<td>Between January 1 and June 1, 2017</td>
</tr>
</tbody>
</table>

(*) For paper submissions: please print and sign in the appropriate spaces:
- Title Page (listing the applicant’s data, Hosting Institution etc.)
- Abstract
- Bio-Ethical requirements page, stamped and signed by the candidate.

Please note that in the Title page two signatures are required: the Legal representative’s and the fellow’s. Should it be difficult to obtain both signatures in the same page (e.g. in case the fellow is not already in the Hosting Institution), it is possible to send separately two paper copies of this page, one with the signature of the fellow, and one with the signature of the Legal representative.

*** Paper documentation marked with “draft” is not valid. Please print the requested pages only after completion of the submission online ***

Send these pages to:
Fondazione Italiana per la Ricerca sul Cancro – AIRC
Peer Review Office
via San Vito 7
20123 Milano

If these documents are not sent by the indicated deadline, or if the Foundation does not receive them, applications will not be sent out for review.

Deadlines for the final report
All deadlines are intended by 5 PM, Central European Time, of the indicated dates.

<table>
<thead>
<tr>
<th>Final scientific report</th>
<th>online form release date</th>
<th>One month prior to the end date of the Fellowship</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>electronic submission deadline</td>
<td>By the end date of the Fellowship</td>
</tr>
</tbody>
</table>

The deadline for the final report may be subjected to changes. In this case, fellows will be notified of the new deadline by e-mail.
Guide to proposal preparation

General information
Candidates must apply via the online portal after setting up a personal account: go to www.airc.it; click on “Area Ricercatori”; click on “Register (for applicants only)” and provide the requested information, including the Italian tax code (codice fiscale), if applicable. Make sure to indicate an e-mail address and phone number where you can be easily reached during all stages of the peer review process; if possible, please include a mobile phone number. The registration will be confirmed by e-mail and a username and password will be provided. You must login to access the application form.

To launch the application form for the first time, click on “Calls”, select “Fellowships”, then click on “Apply” in the Fellowships for Abroad 2016 section. In the next window, click on “Access the application form”. To access the application in progress, click on “Submissions” and then click on “Access the application form”.

Below you will find a list of the general features of our online system:

- all forms that must be filled out are listed on the left side of the page. Click on each one of them and fill in all the mandatory fields (in bold). Make sure to click on “SAVE” after completing each form; it may be necessary to update the page of the browser to see that the information has been saved;
- the forms can be filled out at different times and the work can be interrupted/resumed at any time;
- a number of forms must be submitted as PDF files. Each file cannot exceed 2Mb. Any file exceeding such a limit will be automatically rejected by the system. Secure PDF files cannot be uploaded. Documents submitted as PDF files must be written using an A4 format, single spaced, with margins not less than 2 cm and a font not smaller than 12 point (preferably Palatino, Times, Arial). Do not exceed the page limit indicated for each section: the system will not allow the upload of a number of pages beyond the limit;
- the status of each form is shown on the left: red cross for mandatory forms that are incomplete; yellow circle for not mandatory forms; green mark for completed forms. These same symbols are used in the “Check and Submit” section;
- the “Check and Submit” section (last title in the list of forms on the left) allows applicants to:
  a. check and see whether each form has been correctly filled out; for mandatory forms that are incomplete, the information that must be provided is listed;
  b. view and print the application in its incomplete/complete state. By clicking on “Create draft” and then on “Open submission draft” you can download the PDF draft generated by the system;
  c. submit the application. Once all mandatory forms are complete, please click on “Submit”. Be aware that after clicking on “Submit” it will not be possible to make any further modifications;
- the complete proposal is automatically assembled as a whole PDF file at the end of the online procedure.

The application must be written entirely in English. Applications that do not conform to all the requirements in these instructions will be rejected.
Applicant’s personal data
Most fields are automatically filled out with information provided during the registration into the AIRC website; to modify the information in any of these fields, please click on the link “My personal data” at the bottom of the page and edit the information from the pop-up window. In the “Address” field, please indicate the postal address (home or workplace) where documents related to the fellowship can be mailed to.
Please provide the ORCID identifier, if available. ORCID (Open Researcher and Contributor ID) provides a persistent digital identifier that distinguishes the applicant from every other researcher; for more information, visit the website http://orcid.org/. Although not mandatory, we encourage applicants to register into the ORCID website and then insert their ORCID identifier in the corresponding box in the application.
In the “Education (Undergraduate)” field please enter the details of the undergraduate degree obtained (i.e. the degree that formally allows one to embark on a doctorate in the country where the degree was attained; in Italy, this would be a “laurea magistralis”). In the “Education (PhD)” field, when applicable, please indicate whether you earned a doctorate degree by checking the appropriate box at the “I obtained a PhD” question. If you do hold a PhD, please indicate: the country where you earned it; the research field; the official date it was awarded; the mark/score (write N/A if not applicable); the University.

Type of fellowship
In 2016, only one-year fellowships will be awarded. Please enter the title of the research proposal; it must not exceed 120 characters, small case, spaces included.

Head of the hosting lab
Please fill in the requested fields.

Legal representative
The Legal representative (Legale rappresentante) i.e. the authorized official of the Hosting institution, will be responsible, along with the head of the hosting lab, of all the legal and administrative duties of the fellowship award. Please fill out the requested fields with the contact data of the Legal representative of the Hosting Institution. Please make sure that all data are correct and up-to-date.

Head of the laboratory of origin
Please fill in the requested fields and attach a letter of presentation of the applicant by the head of the lab of origin. The letter must be in letterhead paper, dated and signed, must not exceed one page in length (approx. 500 words, font size 12), and must be uploaded as PDF file.
In case the head of the lab of origin requests the letter of recommendation not to be included in the application, please upload a statement indicating that, in order to maintain confidentiality, the letter will be sent separately to the Peer Review Office. The letter should be sent by e-mail to: airc.direzione-scientifica@airc.it by the deadline of this Call (June 27th 2016).
The Peer Review Office will forward the letter to the reviewers assigned to the application.

Education and training of the applicant
Click on “Add new record” and list all degrees obtained (undergraduate, master’s and doctoral).

Research and professional experience of the applicant
Click on “Add new record” and list all positions held by the applicant after the attainment of the highest degree (e.g. PhD) indicated in the previous section; use this section to list post-doctoral trainings. Do not leave any period unaccounted for.
Research interruptions and justifications
This section should be completed in case the applicant’s research activity has been interrupted for at least 5 months due to parental leave, children care, illness or other personal issues. Click on “Add new record” and fill out the requested fields. This section allows applicants to report prolonged periods of absence from work in the past five years that may have had a negative impact on their track record. Reviewers are instructed to take this information into account when assessing the scientific productivity of an applicant.

Curriculum vitae of the applicant
The Curriculum vitae of the applicant must not exceed the two-page length. The CV, to be uploaded as PDF file, should integrate the biographical sketch outlined in the “Education and training” and “Research and professional experience” sections, and should contain the following information:

• Name of applicant;
• Research experience: for the most relevant entries in the sections “Education and training of the applicant” and “Research and professional experience of the applicant”, please indicate the name of the supervisor and describe very briefly (two-three sentences) the main focus of the research activity carried out;
• Technical skills, competences, clinical activity (if applicable);
• Awards, participation to international meetings and courses.

Do not list the applicant’s publications in the CV, as there is a separate, specific section for this (“Publications of the applicant”, below).

Narrative biosketch
In this section applicants are invited to explain how their education and early experience in a research lab have shaped their motivation and interest in pursuing a career in cancer research. They should also describe how they will benefit from working in the selected hosting lab and why it represents the most suitable place to for their personal and professional development.
Upload the document as PDF file (maximum 1 page, approx. 500 words).

Certificate of graduation
Please upload a copy, in PDF format, of the degree certificate and transcripts (i.e. scores obtained in individual exams). To facilitate the work of reviewers who may not be familiar with the academic transcripts of the applicant’s country, especially if in a language different than English, please include a page with a description (or translation) of the certificate provided and of the score range (e.g. for Italian applicants uploading a certificate of laurea magistralis, please explain that the scores of individual exams range from 18 to 30, 30 being the best score obtainable, and that the final score or voto di laurea can go from 80 to 110, 110 being the best score).

Publications of the applicant
Applicants must provide the list of papers published in the last five years. To do so, a number of options is available; click on any that applies.

Add PubMed publications
Within this interface the system launches a PubMed search and provides a list of PubMed-recorded publications spanning from 2011 to 2016. Enter the applicant’s first and middle initials, and click on “Find”. If the applicant has published with a different last name than that used to register into the AIRC account (e.g. married vs maiden name), check the “Change surname” box, and then click on “Find”. Alternatively, search for a specific article by entering its PubMed ID in the corresponding box. Once the list of all PubMed publications has been generated, please follow these steps:
a. Select papers to be included in the application

From the list of all PubMed publications, select the papers published by the applicant and that the applicant wants to include in the proposal by clicking on the box at the left side of each article. Pay special attention to potential homonyms. Do not include abstracts, conference papers, letters to the editor, book chapters and papers published in journals without IF, unless they are new journals.

b. Indicate acknowledgement to AIRC or the Foundation

For each publication, please indicate whether it has an acknowledgement to AIRC or the Foundation (the box AIRC also comprises acknowledgements to the Foundation; the default is “NO”).

c. Certify accuracy of flags, and save records

Once all selected publications have been flagged, scroll down to the bottom of the page and check the certification box (“I, the undersigned, certify that all publications have been carefully checked and correctly flagged for authorship. I am aware that any mistake or inaccuracy may impact the evaluation of my track record”). The system automatically recognizes the position of the applicant in the list of authors in each publication (if not, the box “not assignable” will be checked). It is possible to amend this information, if incorrect, by providing supporting documentation from the main page of the Publications (see below). Click on “Add selected publications” and then on “Close” to complete the process.

Add Web of Science® publications

From this section it is possible to enter articles that are included in Web of Science® but not in PubMed (most journals are present in both databases, but there are few exceptions; the drop-down menu does not list PubMed journals). For each record, please provide the title, list of authors, journal, year and month of publication, volume, pages. Select the journal from the drop-down menu, which provides all journals listed in Web of Science®. Mark each paper for authorship and acknowledgement to AIRC or the Foundation. Please upload the page of the article where the role of the author in the published work is certified (not the entire manuscript). Finally, check the certification box and click on “Save” to complete the process.

Add papers in press

Use this section to submit articles already accepted for publication but not yet available online. For each record, please provide the title, list of authors, journal, year. Select the journal from the drop-down menu, which lists all Web of Science® indexed journals. Mark each paper for authorship and acknowledgement to AIRC or the Foundation. Please upload a PDF file with the letter of acceptance from the journal. **Do not attach the entire manuscript.** Finally, check the certification box and click on “Save” to complete the process. The IF of papers in press will not be included in the publications table.

Add from MyPub

This interface lists all publications previously entered into the system (either when submitting an application, or when submitting a grant renewal request, or directly into the MyPub section of the Personal Area). By selecting some or all of these publications, they will be uploaded in the current application; please make sure the flags are correct.

All publications entered from any of the above sections will be listed in the “Publications” main page. From here, it is possible to edit the information relative to each paper by clicking on the title of the publication. Once in the “Edit publication flags” window, please check the appropriate authorship box and, if different from the default provided by the system, upload the page of the article where the role of the author in the published work is certified (e.g. for a second or third
author who is in fact a co-first author, please upload the PDF file of the page where it is stated that the applicant “equally contributed to this work”). To complete the process, click on the certification box and click on “Save” to complete the process.

The system will automatically process all publication data to generate the complete list of publications in the PDF of the application, reporting the Impact Factor (IF) of the journals where each paper (with the exception of papers in press) was published.

The candidate is responsible for uploading the most accurate information regarding publications and authorship. The IF assigned to each article, regardless of the publication date, is the latest provided by Thomson Reuters. For this Call, the 2014 Thomson Reuters IF list will be used. Candidates are required to check all the information and to contact the AIRC Peer Review Office before the deadline of the Call in order to correct any possible inaccuracy or mistake.

In case additional papers are accepted for publication after the submission deadline, the applicant may request permission from the AIRC Peer Review Office to add this supplementary information to his/her application. Please prepare a single PDF file containing a copy of the acceptance letter and a copy of the manuscript, and e-mail it to: airc.direzione-scientifica@airc.it. All communications made in this regard by July 24th, 2016 (5 PM Central European Time) will be forwarded to all reviewers evaluating the proposal. Any communication received after July 24th, 2016 will not be taken into consideration.

**Project keywords**

Project keywords will be used by the Peer Review Office to assign each application to the most appropriate reviewers. Therefore, a good choice of keywords is extremely important to ensure that reviewers with the most adequate expertise will evaluate the application. Avoid keywords that are too generic or too similar with each other; pick a set of keywords that clearly define the key aspects of your research plan.

Keywords are listed at the end of this Call both in alphabetical order and by topic. To enter the project keywords (at least one, maximum five) please click on the button “Enter/Edit Keywords”. In the “Manage Project Keywords” pop-up window, keywords are grouped by their first letter: for example, by clicking on the letter “C” in the menu it is possible to visualize all keywords beginning with the letter C, and to select one. Alternatively, type in a specific keyword in the “Search a specific keyword” box and click on “Search”. To select a keyword, click on it (the keyword box will turn from grey to blue) and then click on “Save”. You will be automatically redirected in the main keywords page: click on “Save”. Repeat this process for each keyword. To exit the window, click on “Close”.

**Research project**

The research project, agreed with the head of the hosting laboratory, must be divided into the following sections, all (with the exception of the Abstract) to be uploaded individually as PDF files:

- a. Abstract (structured into: Background, Hypothesis, Aims, Experimental Design, Expected Results and Impact on Cancer. Either type in the text directly into each box, or use a Word processor and then cut and paste each section into the corresponding box; the system allows plain text only. The total number of words must not exceed 500)
- b. Background (max 1 page, approx. 500 words)
- c. Proposal main body (max 3 pages, approx. 1500 words)
- d. Feasibility (max 1 page, approx. 500 words)
- e. References (max 1 page, approx. 15 references).
Please make sure to propose a research plan that is **consistent with the work of one person and with the projected duration of the fellowship**. Proposals that look like a five-year grant requiring the work of several people will be judged not feasible and will be rated very low.

**Letter of acceptance by the Hosting Institution**

Please upload a letter, on letterhead paper, written and signed by the head of the hosting lab (max two pages in length, approx. 1000 words), addressed to the Peer Review Office. The letter MUST include the commitment that Hosting Institution will:

- provide the **necessary lab space and infrastructures**;
- have the **resources** (e.g. research grants held by the supervisor) to carry out the proposed research plan for the entire duration on the fellowship;
- certify that the **fellowship gross amount** is calculated according to the standard costs of living where the Hosting Institution is located and that it matches the standard salary for a fellow at the same career level;
- indicate whether **health and accident insurance coverage** will be provided to the fellow and, if not, please indicate the amount that would be necessary for such insurance so that the fellow can include it in his/her budget;
- make sure that the head of the hosting lab will offer **complementary skills training** (e.g. written skills for preparation of grants and papers, ethical issues and regulations in biotechnologies etc.) and **mentoring activities** with a specific training plan for the fellow (e.g. frequency of one-on-one meetings, lab meetings, participation to seminars and international congresses etc.). Costs for complementary skills training and mentoring must be entirely covered by the Hosting Institution;
- the indication that the fellow will have the **freedom to publish** the results of the research carried out during the fellowship appointment.

Please note that this document is particularly important as it represents the major source of information for reviewers on the mentoring and training opportunities that the fellow will receive. As such, it will impact the **assessment of the “Quality of the Hosting Institution”**, one of the major review criterion (see “The review process” above).

**Education and training of the head of the hosting lab**

Click on “Add new record” and list degrees and post-doctoral trainings of the head of the hosting lab (only the most relevant).

**Research and professional experience of the head of the hosting lab**

Click on “Add new record” and list the most relevant positions held by the head of the hosting lab.

**Publications of the head of the hosting lab**

A list of **the most important** publications of the head of the hosting lab, spanning 2011 to 2016, must be included. Click on “Add publications” and follow the prompt.

**Bio-Ethical Requirements**

Check boxes as applicable for human and animal experimentation.

**Research on humans**

Please note that the term “Research in humans” is not limited to clinical studies with healthy volunteers and/or patients. **It includes use of human biological samples** (commercially available human cell lines *e.g.* from ATCC are exempt), human genetic material and human data collection (*e.g.* genetic information, health, etc.).

If the research plan includes Research in humans, the approval of the Local Ethics Committee or Institutional Review Board (IRB) is mandatory. **The authorization must be valid for the entire duration of the grant** and a copy of such authorization must be provided.
The approval document issued by the Ethics Committee MUST indicate:

- the date when the IRB meeting was held; approvals obtained prior to 2013 are NOT accepted, unless the study protocol is still active (supporting documentation might be requested to verify this is the case);
- the name of the applicant or of a unit of personnel or of a collaborator included in the application;
- a clear reference to the studies described in the proposal (e.g. the title of the application).

In case biospecimens have been obtained by external sources/collaborators, the clearance documents must be provided by the Ethics Committee of the collaborator’s research center.

If the IRB approval is available at the time of submission, check the box “I have obtained the clearance from the competent Ethics Committee/Institutional Review Board…” and upload it as PDF file by clicking on “Select” under the “Research on humans: clearance from Ethics Committee” header. Please indicate the date the approval was released and, if available, the date it expires; check the box “Valid for the duration of the project” if this is the case (supporting documentation might be requested to verify this condition is met).

If the approval from the Ethics Committee is not available by the submission deadline, the candidate must obtain it by November 15th 2016, if possible, or in any case before the fellowship starts. If the application is approved, funds will be granted only after the provision of the approval to the funding bodies. Check the box “I have not obtained the clearance from the competent Ethics Committee/Institutional Review Board yet, but I will provide it…” and, when available, upload it as PDF file in the “Submissions” section of the AIRC account (click on “The following required actions are pending” and on the link “Upload required document”). Alternatively, please send it to the Peer Review Office by e-mail (airc.direzione-scientifica@airc.it).

*Research on animals*

Please check “Yes” if the research plan involves animal experimentation.

If you check “yes”, the following documents must be provided:

- **authorization from the competent animal research ethics committee** and/or from the competent national authority in the country in which the research will be carried out. The authorization must be valid for the entire duration of the fellowship appointment; if it expires during the course of the research project, a new approval must be provided to the funding bodies. If the authorization is not in English, please provide a cover letter summarizing in English the key points of the clearance (e.g. issue and expiration dates, title of project, etc.).

If the authorization is available at the time of the application submission, check the box “I have obtained …” and upload it as PDF file by clicking on “Select” under the “Research on animals: Clearance from Ethics Committee” header. Please indicate the release and expiration date of the authorization in the appropriate boxes.

If the authorization is not available by the application submission deadline, the candidate must obtain it before the start of the project. Check the box “I have not obtained the clearance …” and, when available, upload it as PDF file in the “Submissions” section of the AIRC account: click on “The following required actions are pending” and on the link “Upload required document” and provide the requested documentation and information. Alternatively, please send it to the Peer Review Office by e-mail (airc.direzione-scientifica@airc.it). The fellowship cannot be activated without the necessary authorizations.
• compliance of the research project with the principles of the three Rs. Research supported by the funding bodies that involves animal experimentation must comply with the principle of the Three Rs (3Rs) to Replace, Reduce and Refine the use of animals in research, as required by national and international rules. Please upload a document in the “Research on animals: Principles of the 3Rs” section, describing how the three Rs have been implemented in the research plan (e.g. explain why the anticipated results and benefits of the proposed research justify the use of animals, and why methods avoiding the use of living animals cannot be used; provide details and justification on the number of animals proposed for the research plan; describe all actions that will be taken to avoid or minimize pain and distress; etc.).

By signing the Bio-Ethical requirements page in the PDF file of the application, the applicant declares that the research studies are accurately described in the proposal and conform to all regulations protecting animals used for research purposes, and that the experiments described in the proposal will be performed following the guidelines described in: Wolfensohn S, Lloyd M: "Handbook of Laboratory Animal Management and Welfare, 4th Edition" (Wiley-Blackwell, 2013).

Please note: Ethics Committee(s) approval(s) for human and/or animal research are not necessary for the assessment of the scientific merit of an application, during the review; however, if the application is approved, funds will be granted only if the required Ethical Committee certifications have been sent to the funding bodies. AIRC and the Foundation are not responsible for any inaccuracy in the ethical documentation provided and does not accept any liability for harm to participants in funded trials.

Financial support
Please enter the amount requested (in Euros) in the “Living allowance/year” and the “Travel expenses” boxes; keep in mind that the Living allowance represents the fellowship gross amount: income taxes will be deducted. Please note that the Foundation does not cover Employer’s taxes, therefore these must not be included in the amount requested. Please refer to the “Funding” section and Annex A of the Call for additional details on these allowances. Use the “Costs justification” section to explain how the fellowship gross amount has been determined and, if applicable, please indicate other sources of financial support that the applicant may receive.

In case the Country or the Hosting Institution do not cover health insurance costs, please enter the estimate or quotation of these costs in the “Health insurance/year” box; costs will not be covered by the Foundation if the Hosting Institution is located in a Country of the European Economic Area, with which Italy has agreements in place for sanitary expenses. Should the Hosting Institution cover such costs, enter “0”. In any case, use the “Costs justification” section to detail the situation and any amount requested for this category of expenses.
Proposal PDF Draft
At any time during the application process a PDF draft file of the proposal can be generated and checked: go to “Check and Submit” (on the lower left of the main page), click on “Create draft” and then on “Open submission draft”. It is strongly suggested that after all forms have been correctly filled out, and prior to proceeding with the final submission, the PDF Draft and its content are carefully read, controlled and verified.

Final Full Proposal Submission

Online submission
To electronically submit the application, go to “Check and Submit” (on the lower left of the main page). All mandatory sections of the application form must be completed and must have a green flag before finalizing the submission. Only after having ascertained that all data are correctly reported in the PDF Draft of the proposal, please proceed to proposal submission by clicking on “Submit application”.

The application submitted will be available in PDF format in the “My submissions archive” section in of the Personal Area, and a copy should be saved for future reference.

Paper submission
For paper submission, please print only the following pages:
- Title page;
- Abstract;
- Bio-Ethical requirements page.

Sign and stamp in the appropriate spaces or, in the case of the Abstract, please initial this page. The signatures of the candidate and of the Legal representative are both required in the Title page. By signing the Title page, the candidate and the Legal representative acknowledge and agree to all terms and conditions of this Call.

In addition, the Legal representative declares that should the application be funded, the candidate will be affiliated with the Hosting Institution for the entire duration of the fellowship and will be allowed to carry out the research project in the Hosting Institution. Paper documentation marked with “draft” is not valid. Please print the requested pages only after completion of the submission online.

Send these pages to:

Fondazione Italiana per la Ricerca sul Cancro – AIRC
Peer Review Office
via San Vito 7
20123 Milano

If these documents are not sent by the indicated deadline, or if the Foundation does not receive them, applications will not be sent out for review.
### Addendum A: Living allowance limit

<table>
<thead>
<tr>
<th>Country</th>
<th>Allowance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albania</td>
<td>€ 31,550,00</td>
</tr>
<tr>
<td>Algeria</td>
<td>€ 38,700,00</td>
</tr>
<tr>
<td>Angola</td>
<td>€ 59,550,00</td>
</tr>
<tr>
<td>Argentina</td>
<td>€ 34,250,00</td>
</tr>
<tr>
<td>Armenia</td>
<td>€ 41,550,00</td>
</tr>
<tr>
<td>Austria</td>
<td>€ 54,100,00</td>
</tr>
<tr>
<td>Austria</td>
<td>€ 53,100,00</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>€ 55,500,00</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>€ 29,350,00</td>
</tr>
<tr>
<td>Barbados</td>
<td>€ 60,750,00</td>
</tr>
<tr>
<td>Belarus</td>
<td>€ 35,050,00</td>
</tr>
<tr>
<td>Belgium</td>
<td>€ 50,000,00</td>
</tr>
<tr>
<td>Belize</td>
<td>€ 37,650,00</td>
</tr>
<tr>
<td>Benin</td>
<td>€ 46,500,00</td>
</tr>
<tr>
<td>Bolivia</td>
<td>€ 33,050,00</td>
</tr>
<tr>
<td>Bosnia Erzegovina</td>
<td>€ 37,300,00</td>
</tr>
<tr>
<td>Botswana</td>
<td>€ 31,600,00</td>
</tr>
<tr>
<td>Brazil</td>
<td>€ 56,000,00</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>€ 31,350,00</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>€ 48,350,00</td>
</tr>
<tr>
<td>Cambodia</td>
<td>€ 42,750,00</td>
</tr>
<tr>
<td>Cameroon</td>
<td>€ 46,650,00</td>
</tr>
<tr>
<td>Canada</td>
<td>€ 47,100,00</td>
</tr>
<tr>
<td>Capo Verde</td>
<td>€ 37,100,00</td>
</tr>
<tr>
<td>Cent. African Rep.</td>
<td>€ 50,650,00</td>
</tr>
<tr>
<td>Chad</td>
<td>€ 55,900,00</td>
</tr>
<tr>
<td>Chile</td>
<td>€ 34,650,00</td>
</tr>
<tr>
<td>China</td>
<td>€ 50,100,00</td>
</tr>
<tr>
<td>Colombia</td>
<td>€ 47,400,00</td>
</tr>
<tr>
<td>Congo</td>
<td>€ 58,350,00</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>€ 46,650,00</td>
</tr>
<tr>
<td>Côte d'Ivoire</td>
<td>€ 48,400,00</td>
</tr>
<tr>
<td>Croatia</td>
<td>€ 41,500,00</td>
</tr>
<tr>
<td>Cuba</td>
<td>€ 41,250,00</td>
</tr>
<tr>
<td>Cyprus</td>
<td>€ 41,850,00</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>€ 42,100,00</td>
</tr>
<tr>
<td>Dem. Rep. Congo</td>
<td>€ 73,800,00</td>
</tr>
<tr>
<td>Denmark</td>
<td>€ 67,050,00</td>
</tr>
<tr>
<td>Djibouti</td>
<td>€ 54,850,00</td>
</tr>
<tr>
<td>Dominican Rep.</td>
<td>€ 35,350,00</td>
</tr>
<tr>
<td>Ecuador</td>
<td>€ 40,300,00</td>
</tr>
<tr>
<td>Egypt</td>
<td>€ 29,700,00</td>
</tr>
<tr>
<td>El Salvador</td>
<td>€ 39,950,00</td>
</tr>
<tr>
<td>Estonia</td>
<td>€ 37,800,00</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>€ 45,450,00</td>
</tr>
<tr>
<td>Fiji</td>
<td>€ 32,300,00</td>
</tr>
<tr>
<td>Finland</td>
<td>€ 59,700,00</td>
</tr>
<tr>
<td>France</td>
<td>€ 58,050,00</td>
</tr>
<tr>
<td>FYROM</td>
<td>€ 30,250,00</td>
</tr>
<tr>
<td>Gabon</td>
<td>€ 52,200,00</td>
</tr>
<tr>
<td>Gabon</td>
<td>€ 42,800,00</td>
</tr>
<tr>
<td>Ghana</td>
<td>€ 36,500,00</td>
</tr>
<tr>
<td>Germany</td>
<td>€ 47,400,00</td>
</tr>
<tr>
<td>Ghana</td>
<td>€ 36,500,00</td>
</tr>
<tr>
<td>Greece</td>
<td>€ 47,400,00</td>
</tr>
<tr>
<td>Guatemala</td>
<td>€ 39,800,00</td>
</tr>
<tr>
<td>Guinea</td>
<td>€ 33,800,00</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>€ 47,600,00</td>
</tr>
<tr>
<td>Guyana</td>
<td>€ 34,550,00</td>
</tr>
<tr>
<td>Haiti</td>
<td>€ 54,100,00</td>
</tr>
<tr>
<td>Haiti</td>
<td>€ 54,100,00</td>
</tr>
<tr>
<td>Honduras</td>
<td>€ 41,350,00</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>€ 54,500,00</td>
</tr>
<tr>
<td>Hungary</td>
<td>€ 39,600,00</td>
</tr>
<tr>
<td>Iceland</td>
<td>€ 47,500,00</td>
</tr>
<tr>
<td>Indonesia</td>
<td>€ 42,650,00</td>
</tr>
<tr>
<td>Ireland</td>
<td>€ 54,550,00</td>
</tr>
<tr>
<td>Israel</td>
<td>€ 54,900,00</td>
</tr>
<tr>
<td>Jamaica</td>
<td>€ 53,500,00</td>
</tr>
<tr>
<td>Japan</td>
<td>€ 75,050,00</td>
</tr>
<tr>
<td>Jordan</td>
<td>€ 49,100,00</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>€ 48,150,00</td>
</tr>
<tr>
<td>Kenya</td>
<td>€ 41,650,00</td>
</tr>
<tr>
<td>Kosovo</td>
<td>€ 30,450,00</td>
</tr>
<tr>
<td>Laos</td>
<td>€ 42,500,00</td>
</tr>
<tr>
<td>Latvia</td>
<td>€ 37,150,00</td>
</tr>
<tr>
<td>Lebanon</td>
<td>€ 43,850,00</td>
</tr>
<tr>
<td>Lesotho</td>
<td>€ 34,350,00</td>
</tr>
<tr>
<td>Liberia</td>
<td>€ 54,150,00</td>
</tr>
<tr>
<td>Libya</td>
<td>€ 31,200,00</td>
</tr>
<tr>
<td>Liechtenstein</td>
<td>€ 54,950,00</td>
</tr>
<tr>
<td>Lithuania</td>
<td>€ 36,250,00</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>€ 50,000,00</td>
</tr>
<tr>
<td>Madagascar</td>
<td>€ 40,750,00</td>
</tr>
<tr>
<td>Malawi</td>
<td>€ 44,900,00</td>
</tr>
<tr>
<td>Malaysia</td>
<td>€ 40,150,00</td>
</tr>
<tr>
<td>Mali</td>
<td>€ 50,100,00</td>
</tr>
<tr>
<td>Malta</td>
<td>€ 41,100,00</td>
</tr>
<tr>
<td>Mauritania</td>
<td>€ 33,650,00</td>
</tr>
<tr>
<td>Mauritius</td>
<td>€ 40,050,00</td>
</tr>
<tr>
<td>Mexico</td>
<td>€ 39,000,00</td>
</tr>
<tr>
<td>Moldova</td>
<td>€ 32,150,00</td>
</tr>
<tr>
<td>Montenegro</td>
<td>€ 32,500,00</td>
</tr>
<tr>
<td>Morocco</td>
<td>€ 39,000,00</td>
</tr>
<tr>
<td>Mozambique</td>
<td>€ 35,150,00</td>
</tr>
<tr>
<td>Namibia</td>
<td>€ 43,100,00</td>
</tr>
<tr>
<td>Nepal</td>
<td>€ 41,630,00</td>
</tr>
<tr>
<td>Netherlands</td>
<td>€ 52,050,00</td>
</tr>
<tr>
<td>New Caledonia</td>
<td>€ 56,750,00</td>
</tr>
<tr>
<td>New Zealand</td>
<td>€ 50,150,00</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>€ 31,650,00</td>
</tr>
<tr>
<td>Niger</td>
<td>€ 44,050,00</td>
</tr>
<tr>
<td>Nigeria</td>
<td>€ 49,500,00</td>
</tr>
<tr>
<td>Norway</td>
<td>€ 70,300,00</td>
</tr>
<tr>
<td>Pakistan</td>
<td>€ 26,050,00</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>€ 51,700,00</td>
</tr>
<tr>
<td>Peru</td>
<td>€ 45,850,00</td>
</tr>
<tr>
<td>Philippines</td>
<td>€ 39,250,00</td>
</tr>
<tr>
<td>Poland</td>
<td>€ 38,550,00</td>
</tr>
<tr>
<td>Portugal</td>
<td>€ 42,500,00</td>
</tr>
<tr>
<td>Romania</td>
<td>€ 34,750,00</td>
</tr>
<tr>
<td>Russia</td>
<td>€ 53,750,00</td>
</tr>
<tr>
<td>Rwanda</td>
<td>€ 48,700,00</td>
</tr>
<tr>
<td>Samoa</td>
<td>€ 46,050,00</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>€ 40,350,00</td>
</tr>
<tr>
<td>Senegal</td>
<td>€ 45,150,00</td>
</tr>
<tr>
<td>Senegal</td>
<td>€ 45,150,00</td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>€ 54,000,00</td>
</tr>
<tr>
<td>Singapore</td>
<td>€ 60,400,00</td>
</tr>
<tr>
<td>Slovak Republic</td>
<td>€ 40,000,00</td>
</tr>
<tr>
<td>Slovenia</td>
<td>€ 44,800,00</td>
</tr>
<tr>
<td>Solomon Islands</td>
<td>€ 55,550,00</td>
</tr>
<tr>
<td>South Africa</td>
<td>€ 33,900,00</td>
</tr>
<tr>
<td>Spain</td>
<td>€ 48,850,00</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>€ 40,700,00</td>
</tr>
<tr>
<td>Sudan</td>
<td>€ 44,150,00</td>
</tr>
<tr>
<td>Suriname</td>
<td>€ 31,500,00</td>
</tr>
<tr>
<td>Swaziland</td>
<td>€ 35,900,00</td>
</tr>
<tr>
<td>Sweden</td>
<td>€ 59,300,00</td>
</tr>
<tr>
<td>Switzerland</td>
<td>€ 59,800,00</td>
</tr>
<tr>
<td>Syria</td>
<td>€ 45,150,00</td>
</tr>
<tr>
<td>Taiwan</td>
<td>€ 44,900,00</td>
</tr>
<tr>
<td>Tajikistan</td>
<td>€ 35,100,00</td>
</tr>
<tr>
<td>Tanzania</td>
<td>€ 38,300,00</td>
</tr>
<tr>
<td>Thailand</td>
<td>€ 41,000,00</td>
</tr>
<tr>
<td>The Faroes</td>
<td>€ 67,050,00</td>
</tr>
<tr>
<td>Timor Leste</td>
<td>€ 49,700,00</td>
</tr>
<tr>
<td>Togo</td>
<td>€ 43,000,00</td>
</tr>
<tr>
<td>Trinidad and Tobago</td>
<td>€ 45,750,00</td>
</tr>
<tr>
<td>Tunisia</td>
<td>€ 36,000,00</td>
</tr>
<tr>
<td>Turkey</td>
<td>€ 49,200,00</td>
</tr>
<tr>
<td>Uganda</td>
<td>€ 35,150,00</td>
</tr>
<tr>
<td>Ukraine</td>
<td>€ 39,100,00</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>€ 67,200,00</td>
</tr>
<tr>
<td>US</td>
<td>€ 50,500,00</td>
</tr>
<tr>
<td>Uruguay</td>
<td>€ 47,100,00</td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>€ 28,200,00</td>
</tr>
<tr>
<td>Vanuatu</td>
<td>€ 60,000,00</td>
</tr>
<tr>
<td>Venezuela</td>
<td>€ 40,550,00</td>
</tr>
<tr>
<td>Vietnam</td>
<td>€ 28,850,00</td>
</tr>
<tr>
<td>West Bank</td>
<td>€ 57,850,00</td>
</tr>
<tr>
<td>Yemen</td>
<td>€ 36,500,00</td>
</tr>
<tr>
<td>Zambia</td>
<td>€ 39,850,00</td>
</tr>
<tr>
<td>South Korea</td>
<td>€ 53,100,00</td>
</tr>
</tbody>
</table>
Template - Agreement for the provision of fellowship awards funded by Fondazione Italiana per la Ricerca sul Cancro - AIRC

BETWEEN

Fondazione Italiana per la Ricerca sul Cancro - AIRC, hereinafter referred to as the Foundation with registered office in (full address, including Country), (tax code – if applicable) represented by (name of Legal Representative and position held, e.g. Dean, Head of research administration, etc.).

AND

(Name of Institution) hereinafter referred to as the Hosting Institution, located in (full address, including Country), (tax code – if applicable) represented by (name of Legal Representative and position held, e.g. Dean, Head of research administration, etc.).

WHEREAS

1. The Foundation is a not-for-profit organization, with the only mission to support cancer research with funds obtained through bequests and donations;
2. Each year the Foundation issues Calls for fellowship applications;
3. Awardees are selected by the Foundation after a careful assessment of the scientific merit of all fellowship applications through the internationally recognized peer review system: each application is evaluated by three external reviewers in compliance with conflict of interests rules. Reviewers are chosen among leading international scientists working in research institutions outside of Italy (a panel of over 600) and/or researchers belonging to the Technical Review Committee (Comitato Tecnico Scientifico, CTS), with expertise in the various fields of cancer research;
4. Within the 2016 Call Dr. XXX has been awarded a fellowship to carry out the research plan: “XXX” under the supervision of Dr. XXX, from XXX to XXXX;
5. The research plan outlined in the fellowship application must be undertaken in not-for-profit organizations that have, among their purposes, the mission of conducting scientific research on cancer. The hosting institution is willing to take on the fellow, making resources and facilities available so that he/she can carry out the proposed research activity;
6. The Foundation will transfer the gross amount of the fellowship award to the Hosting Institution.

NOW THEREFORE

the parties agree to the following terms and conditions:

Article 1 – Terms and conditions for the transfer of funds from the Foundation to the Hosting Institution
The Foundation will transfer Dr. …..’s fellowship gross amount of Euro ….. (….) to the Hosting Institution, in local currency. The Foundation will make three-monthly bank wire transfers in advance.

Wire transfers will be made by the Foundation to the financial institution indicated below, selected by the Hosting Institution:
NAME OF BANK:  
BRANCH:  
BANK ADDRESS:  
ACCOUNT NUMBER:  
NAME OF BANK ACCOUNT HOLDER:  
IBAN (if in Europe):  
SWIFT CODE (if in USA and/or Europe):  
ROUTING NUMBER (if in USA):  

The Hosting Institution must promptly notify the Foundation should there be any change in the bank data above.

**Article 2 - Terms and conditions for the provision of the fellowship award to the fellow**

The Hosting Institution shall grant the fellowship award remuneration through monthly payments, applying the local regulation for employment and tax in force. The Hosting Institution is in charge of all legal, fiscal and administrative responsibilities associated with the management of the fellowship. No bank charges, management fees or administrative costs can be withheld from the fellowship gross amount. The Foundation does not act as an employer with respect to the fellow. The Hosting Institution and the fellow should reach an agreement on the most convenient contractual provision to be applied, based on the amount of the fellowship award and the applicable local law and jurisdiction.

The Hosting Institution must ensure proper financial management of the award, maintaining relevant salary records. The Hosting Institution must complete and return a financial reconciliation statement within three months from the end date of the fellowship award.

**Article 3 – Responsibilities and obligations of the Hosting Institution**

It is the Hosting Institution’s responsibility to ensure that the fellow’s research project can be carried out. To this aim, the Hosting Institution will operate autonomously, abiding by all applicable laws and regulations, and will not require the involvement of the Foundation in its interactions or associations with third parties (e.g. employees, collaborators, contractors, etc.). The Foundation accepts no liabilities with regard to losses or damages directly or indirectly resulting from the fellowship research activities.

The provision of the fellowship award must be in compliance with the local laws and regulations. It is the responsibility of the Hosting Institution to comply with occupational safety and health standards issued by the local jurisdiction, and to provide fellows with a liability insurance, an insurance against occupational injuries and/or illnesses, and possibly a medical insurance. In case the latter cannot be granted, the Hosting Institution must promptly notify the Foundation.

The Hosting Institution must have, throughout the duration of the fellowship appointment, adequate and appropriate means (including the infrastructure, equipment and products) for implementing the research project. The Hosting Institution must meet all the necessary legal and regulatory requirements and must have obtained all the necessary licenses and approvals in order to conduct the research. In addition, it must ensure proper training of the fellow under the supervision of the head of the hosting lab indicated in the fellowship application.

**Article 4 – Responsibilities and obligations of the Foundation**

The financial contribution provided by the Foundation will not exceed the amount indicated in the official notification of the awardees as per Article 1 of this agreement. The Hosting Institution will cover all additional costs associated with the activation, management and implementation of the fellow’s research activities.

**Article 5 – Variation and termination**
The Hosting Institution must promptly notify the Foundation of any change to the terms and conditions of the award (e.g. change in status of the Hosting Institution, research interruptions for maternity, etc.). Proposed modifications must be examined and approved by the Office of the Scientific Director before they can be effected. Please send all requests of variation by e-mail to: Administrative.office@airc.it

In case the research activities must be interrupted for more than 40 consecutive days (e.g. maternity leave or illness, confirmed by a medical certificate), the fellowship award will be suspended and the termination date will be postponed accordingly. In this case, the Hosting Institution must notify the Foundation indicating the start and end date of the interruption, together with the new fellowship termination date agreed with the fellow. The Foundation will reschedule the wire transfers based on this information.

Should the fellow decide to terminate the fellowship appointment prior to the official end date, the Hosting Institution and the fellow must promptly notify the Foundation with an official resignation letter, signed by the fellow and the supervisor. With the early termination of the fellowship award, the research project will terminate as well. The Foundation will immediately suspend all remaining payments. Within two months from the official letter of resignation, residual funds already transferred by the Foundation to the Hosting Institution and not used for the fellow’s wage must be returned to the Foundation, wiring them to:

NAME OF BANK:
ACCOUNT NUMBER:
NAME OF BANK ACCOUNT HOLDER:
IBAN:
SWIFT CODE:

**Article 6 – Acknowledgements**
Each publication, press release or other document or media communication citing results from the research carried out during the fellowship appointment must include an acknowledgement to the Foundation.

**Article 7 – Duration**
This agreement will be effective after the Institutional Authorized Official of each party has initialed each page of this document and dated and signed the last page. The agreement is valid for the entire duration of the fellowship appointment.

**Article 8 – Privacy**
Each party agrees to protect the confidentiality of all data included in this Agreement, and to use and process them (electronically and/or manually) only for the purposes of the agreement and the management of the fellowship award. To this aim, access to data must be restricted to a limited number of authorized users. Information may be disclosed, when required, to comply with national laws, rules and directives. Data may also be disclosed to third parties for statistical analyses, but only if identifiable information on the fellow, the Foundation and the Hosting Institution is removed.

**Article 9 – Communications**
Any communication regarding this agreement, or any request for modifications, must be transmitted to the following e-mail addresses:
Administrative.office@airc.it (for communications to the Foundation)
(please enter a valid e-mail address) (for communications to the Hosting Institution)
The Hosting Institution must promptly notify the Foundation of any of the following: variation in its status that may affect its eligibility to serve as Hosting Institution as defined in point 5 of the introduction of this agreement; variation in its legal status (e.g. mergers, acquisitions, etc.); significant variations in its organizational structure; variation in its relationship with the fellow; transfer of the fellow to a different research institution; bankruptcy, lawsuits or any other significant issue that might compromise the financial solidity of the Hosting Institution.

Article 10 – Dispute resolution
This agreement is governed exclusive by the laws of Italy. The parties will attempt in good faith to resolve through negotiation any dispute, claim or controversy relating to this agreement. Should these attempts not be effective, the parties will try to resolve the disagreement by filing a request for arbitration with the International Court of Arbitration.

Article 11 – Additional documents
The fellowship award is regulated by the terms and conditions of this agreement together with the guidelines included in the appropriate the Foundation Call for fellowship applications. Also, additional directives may be contained within the Fellowship award notification letter.

IN WITNESS WHEREOF

The parties have executed this Agreement by their respective authorized officials as of the date of the last signature.

Fondazione Italiana per la Ricerca sul Cancro - AIRC
Milan,
Institutional Authorized Official: , Chairman
Signature and Stamp:

Hosting Institution
(Place, date: day – month – year)
Institutional Authorized Official: (name and title)
Signature and Stamp:
<table>
<thead>
<tr>
<th>Acute Lymphoblastic Leukemia (ALL)</th>
<th>CD133/Stem cell markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Myeloid Leukemia (AML)</td>
<td>Cell adhesion and/or cell adhesion molecules</td>
</tr>
<tr>
<td>Adenovirus</td>
<td>Cell cycle</td>
</tr>
<tr>
<td>Adjuvant therapy</td>
<td>Cell cycle checkpoint G1/S</td>
</tr>
<tr>
<td>Aging and cancer</td>
<td>Cell cycle checkpoint G2/M</td>
</tr>
<tr>
<td>AIDS/HIV/Kaposi</td>
<td>Cell differentiation and/or differentiation therapy</td>
</tr>
<tr>
<td>Androgen and/or receptors</td>
<td>Cell migration, motility and/or invasion</td>
</tr>
<tr>
<td>Aneuploidy</td>
<td>Cell polarity</td>
</tr>
<tr>
<td>Angiogenesis and/or vasculogenesis</td>
<td>Cell signaling</td>
</tr>
<tr>
<td>Animal models</td>
<td>Centrosome</td>
</tr>
<tr>
<td>Anti-angiogenic therapy</td>
<td>Cervix or endometrial ca.</td>
</tr>
<tr>
<td>Antibody/mAb therapy</td>
<td>Chemistry</td>
</tr>
<tr>
<td>Apoptosis</td>
<td>Chemoimmunotherapy</td>
</tr>
<tr>
<td>Aromatase and/or inhibitors</td>
<td>Chemokines</td>
</tr>
<tr>
<td>ATM pathway</td>
<td>Chemotherapy and/or chemotherapeutic drugs</td>
</tr>
<tr>
<td>ATR pathway</td>
<td>Chromatin remodeling</td>
</tr>
<tr>
<td>Autoimmunity/Autoantibodies</td>
<td>Chronic Lymphocytic Leukemia (CLL)</td>
</tr>
<tr>
<td>Autophagy</td>
<td>Chronic Myeloid Leukemia (CML)</td>
</tr>
<tr>
<td>B cells</td>
<td>Circulating tumor cells</td>
</tr>
<tr>
<td>bcl2 family</td>
<td>Clinical practice guidelines</td>
</tr>
<tr>
<td>BCR-Abl/Abl</td>
<td>Clinical trials</td>
</tr>
<tr>
<td>Biochemistry</td>
<td>Colorectal and/or Intestinal ca.</td>
</tr>
<tr>
<td>Bioinformatics</td>
<td>Combination therapy</td>
</tr>
<tr>
<td>Biomarkers</td>
<td>Comparative genomics hybridization (CGH)</td>
</tr>
<tr>
<td>Biomolecular modelling</td>
<td>Computational biology</td>
</tr>
<tr>
<td>Biophysics</td>
<td>Computer Tomography (CT Scan)</td>
</tr>
<tr>
<td>Bladder tumor</td>
<td>Costimulatory molecules</td>
</tr>
<tr>
<td>Body mass index (BMI) and/or obesity</td>
<td>COX2</td>
</tr>
<tr>
<td>Bone disease</td>
<td>Crosstalk</td>
</tr>
<tr>
<td>Bone morphogenetic protein (BMP)</td>
<td>Crystallography</td>
</tr>
<tr>
<td>BRAF/RAF kinases</td>
<td>Cyclic AMP</td>
</tr>
<tr>
<td>Brain and/or nervous system tumors</td>
<td>Cyclins and/or inhibitors</td>
</tr>
<tr>
<td>BRCA</td>
<td>Cytogenetics and/or chromosome alterations</td>
</tr>
<tr>
<td>Breast ca.</td>
<td>Cytokines/Interleukins</td>
</tr>
<tr>
<td>Burkitt lymphoma</td>
<td>Cytokinesis</td>
</tr>
<tr>
<td>C.elegans</td>
<td>Cytoskeleton</td>
</tr>
<tr>
<td>Cachexia</td>
<td>Cytotoxic T Lymphocytes (CTL)</td>
</tr>
<tr>
<td>Cadherins</td>
<td>Dendritic cells</td>
</tr>
<tr>
<td>Cancer evolution</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>Cancer stem cells</td>
<td>Diet</td>
</tr>
<tr>
<td>Carcinogenesis</td>
<td>DNA damage</td>
</tr>
<tr>
<td>Caspases</td>
<td>DNA double strand break repair (DSBR)</td>
</tr>
<tr>
<td>Caveolin</td>
<td>DNA methylation</td>
</tr>
</tbody>
</table>
KEYWORDS IN ALPHABETICAL ORDER

DNA recombination
DNA repair
DNA replication
DNA single strand break repair (SSBR)
Docking
Drosophila
Drug delivery
Drug discovery and/or development
Drug response and/or resistance
Drug screening
Drug toxicity
EGF and/or receptors
Embryonic development
Endocrinology
Endocytosis
Endoplasmic reticulum (ER)
Endothelial cells
Epidemiology
Epigenetics
Epithelial mesenchyme transition (EMT)
Epstein-Barr Virus (EBV)
Estrogens and/or receptors
Exosomes and/or endogenous microvesicles
Extracellular Matrix (ECM)/Stroma
Fas and/or FasL
Fatty acids
FGF and/or receptor
Flow cytometry
Fluence imaging system
Fluorescence in situ hybridization (FISH)
Fluorescence resonance energy transfer (FRET)
Focal Adhesion/FAK
Folate and/or receptor
Functional genomics
Functional validation of target genes
Fusion genes
Gastric ca.
Gene alteration/gain or loss
Gene expression and/or profile
Gene regulation
Gene therapy
Genetics
Genome wide screening/GWAS
Genomic imprinting
Genomic/Genetic instability
Genomics
Genotoxicity
Glioma and/or glioblastoma
Glucocorticoids and/or receptors
Glucose metabolism and/or Warburg effect
Glycoproteins and/or glycosylation
Golgi
G-proteins and/or GPCR
Granulocytes
Growth factors and/or receptors
Growth induction and/or growth arrest
GVDH and/or Graft versus Tumor
Gynecological tumors
Head and neck ca.
Heat shock proteins (HSP)
Hedgehog pathway
Hematologic malignancies
Hematopoiesis
Hematopoietic stem cells
Hemostasis and thrombosis
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Hepatocellular carcinoma (HCC)
HER1-2-3-4
Hereditary DNA repair disorders
Hereditary tumors
Herpes virus
High Mobility Group Proteins (HMG)
Hippo pathway
Histone modifications
HLA/Major Histocompatibility Complex (MHC)
Hodgkin's lymphoma
Homologous recombination
Hormones
Human Papilloma Virus (HPV)
Hypoxia/Hypoxia-inducible Factors (HIF-1)
Immune escape
Immunization
Immunoo-editing
Immunohistochemistry
Immunosuppression and/or suppressor cells
<table>
<thead>
<tr>
<th>Keyword</th>
<th>Keyword</th>
<th>Keyword</th>
<th>Keyword</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunotherapy</td>
<td>Microbiome</td>
<td>Microenvironment</td>
<td>mRNA processing</td>
</tr>
<tr>
<td>In vitro imaging and/or live cell imaging</td>
<td>MicroRNA</td>
<td>Microscopy</td>
<td>mRNA translation</td>
</tr>
<tr>
<td>In vivo imaging</td>
<td>Minimal Residual Disease (MRD)</td>
<td>Mitochondria</td>
<td>mRNA translation</td>
</tr>
<tr>
<td>Infection</td>
<td>Mitosis</td>
<td>Monoclonal antibodies (mAbs) and/or immunoconjugates</td>
<td>Mitosis</td>
</tr>
<tr>
<td>Inflammation and/or inflammatory cytokines</td>
<td>Mouse models</td>
<td>mRNA processing</td>
<td>Multiprotein</td>
</tr>
<tr>
<td>Inhibitor of apoptosis proteins (IAPs)</td>
<td>mRNA translation</td>
<td>Multidrug resistance (MDR)</td>
<td>Neuroblastoma</td>
</tr>
<tr>
<td>Innate immunity</td>
<td>Mutation (somatic and/or germline)</td>
<td>Neuroendocrine tumors</td>
<td>Neuroendocrine tumors</td>
</tr>
<tr>
<td>Insulin</td>
<td>Myc</td>
<td>Myeloma</td>
<td>Neuroendocrine tumors</td>
</tr>
<tr>
<td>Insulin-like growth factor (IGF) and/or receptors</td>
<td>Nanotechnology/Nanoparticles</td>
<td>NF-kB family</td>
<td>Neuroendocrine tumors</td>
</tr>
<tr>
<td>Integrins and/or Integrin-linked kinase (ILK)</td>
<td>NMR spectroscopy</td>
<td>Nitric oxide</td>
<td>Neuroendocrine tumors</td>
</tr>
<tr>
<td>Interferons</td>
<td>NK and/or NKT cells</td>
<td>NMG spectroscopy</td>
<td>Non apoptotic cell death</td>
</tr>
<tr>
<td>Ion channels</td>
<td>Next generation sequencing</td>
<td>Notch pathway</td>
<td>Non apoptosis cell death</td>
</tr>
<tr>
<td>Jak/Stat pathway</td>
<td>NF-kB family</td>
<td>Nuclear medicine</td>
<td>Non melanoma skin tumors</td>
</tr>
<tr>
<td>Kidney ca.</td>
<td>NK and/or NKT cells</td>
<td>Nuclear receptor</td>
<td>Normal stem cells</td>
</tr>
<tr>
<td>Kinase/Kinome</td>
<td>Non apoptotic cell death</td>
<td>Oncogenes</td>
<td>Normal stem cells</td>
</tr>
<tr>
<td>Lentivirus</td>
<td>Non apoptotic cell death</td>
<td>Oncogenes</td>
<td>Organic compounds</td>
</tr>
<tr>
<td>Leukaemia</td>
<td>Non melano skin tumors</td>
<td>Oncogenes</td>
<td>Organic compounds</td>
</tr>
<tr>
<td>Lipid metabolism</td>
<td>Ovarian ca.</td>
<td>Oncogenes</td>
<td>Organic compounds</td>
</tr>
<tr>
<td>Lipidic mediators</td>
<td>Oxidative stress and/or Reactive Oxygen Species (ROS)</td>
<td>Oxidative stress and/or Reactive Oxygen Species (ROS)</td>
<td>Osteosarcoma</td>
</tr>
<tr>
<td>Lipoxygenases</td>
<td>p21 - activated kinases (PAK)</td>
<td>p21 - activated kinases (PAK)</td>
<td>Osteosarcoma</td>
</tr>
<tr>
<td>Liver development and/or regeneration</td>
<td>p53, p63, p73</td>
<td>p53, p63, p73</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Loss of heterozygosity (LOH)</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Lung ca.</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Lymphatics and/or lymphangiogenesis</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Lymphocyte differentiation</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Lymphomas</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Macrophages and/or monocytes</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Magnetic resonance imaging (MRI)</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>MAP Kinases</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Mass spectrometry</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Mathematical modeling</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Mathematical oncology</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Matrix metalloproteases (MMP) and/or inhibitors</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>MDM2</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Pathology</td>
<td>Pathology</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Membrane biology</td>
<td>Ovarian ca.</td>
<td>Ovarian ca.</td>
<td>Oxidative stress and/or Reactive Oxygen Species (ROS)</td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>Oxidative stress and/or Reactive Oxygen Species (ROS)</td>
<td>Oxidative stress and/or Reactive Oxygen Species (ROS)</td>
<td>Oxidative stress and/or Reactive Oxygen Species (ROS)</td>
</tr>
<tr>
<td>MET/HGF</td>
<td>p21 - activated kinases (PAK)</td>
<td>p21 - activated kinases (PAK)</td>
<td>Oxidative stress and/or Reactive Oxygen Species (ROS)</td>
</tr>
<tr>
<td>Metabolism/Metabolomics</td>
<td>p53, p63, p73</td>
<td>p53, p63, p73</td>
<td>Oxidative stress and/or Reactive Oxygen Species (ROS)</td>
</tr>
<tr>
<td>Metallo-drugs</td>
<td>Palliative care</td>
<td>Palliative care</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Metastasis</td>
<td>Palliative care</td>
<td>Palliative care</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Microarrays</td>
<td>Palliative care</td>
<td>Palliative care</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Mathematical oncology</td>
<td>Palliative care</td>
<td>Palliative care</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Pathology</td>
<td>Palliative care</td>
<td>Palliative care</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Pathology</td>
<td>Palliative care</td>
<td>Palliative care</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Pathology</td>
<td>Palliative care</td>
<td>Palliative care</td>
<td>Palliative care</td>
</tr>
</tbody>
</table>
KEYWORDS IN ALPHABETICAL ORDER

Patient risk stratification
PDGF and/or receptors
Pediatric tumors
Peptides as drugs
Peroxisome proliferator-activated receptor (PPAR)
PET and/or PET-CT
Phage display
Phagocytes and/or phagocytosis
Pharmacogenetics/Pharmacogenomics
Pharmacokinetics
Pharmacology
Phosphatases
Phospholipids
Phosphorylation
Photodynamic therapy and photodetection
Photonics
PI3K/Akt/PTEN/mTOR pathway
Poly-ADP-ribose polymerase (PARP)
Polymorphisms/SNPs
Post-translational modification
Precancerous lesions
Preclinical studies
Prevention and/or chemoprevention
Prognosis
Prostaglandins
Prostate ca.
Proteasome
Protein microarrays
Proteomics
Proteasome
Radionuclide therapy
Radiosensitivity and/or resistance
Radiotherapy
Radiotoxicity
RAS/RAS inhibitors
Rb/Rb family
Response and/or resistance to therapy
RET
Retinoblastoma
Retinoic acid and/or receptors
Retrospective studies
Rho GTPases family
Risk factors
RNA binding proteins

RNA splicing
Sarcoma
Screening
Senescence
Side effects
Signal transduction inhibitors
siRNA and/or non coding RNA
Small molecule inhibitors
Smoking
Soft tissue tumors
Solid tumors
SPECT
Spheroids/3D cultures
Src family
Staging
Statistics
Stress response
SUMO and/or sumoylation
Surgery
Survival analysis
Synthetic lethality
Systems biology
T cells/TCR
T helpers
Target therapy
Telomere and/or telomerase
Testis ca.
TGF and/or receptors
Thymoma
Thyroid ca.
Thyroid hormone
Tissue microarrays (TMA)
TNF and/or receptors
Tolerance
Toll-like receptors (TLR)
Topoisomerase
TRAIL
Transcription
Transcription factors
Transformation assays
Transgenic mice
Translesion synthesis
Translocation
Transplantation
Treg cells
Triple negative breast ca.
Tumor antigen
Tumor dormancy
Tumor-infiltrating Lymphocytes (TIL)
Tumor suppressor genes
Tumor-stroma interaction
Tyrosine kinase receptors (TKR) and/or inhibitors
Ubiquitin and/or ubiquitination
Ultrasound
Urokinase-Plasminogen System (uPA, uPAR, PAI)
Vaccine
VEGF and/or receptor
Virology
Von Hippel-Lindau (VHL)
Wilms' Tumor Gene (WT1)
Wnt/beta-catenin pathway
Xenopus
Yeast
Zebrafish
KEYWORDS BY TOPIC

**Adhesion and stroma**
- Cadherins
- Caveolin
- Cell adhesion and/or cell adhesion molecules
- Cell migration, motility and/or invasion
- Cell polarity
- Cytoskeleton
- Extracellular Matrix (ECM)/Stroma
- Focal Adhesion/FAK
- Integrins and/or Integrin-linked kinase (ILK)
- Matrix metalloproteases (MMP) and/or inhibitors
- Microenvironment
- Osteopontin
- Tumor-stroma interaction
- Urokinase-Plasminogen System (uPA, uPAR, PAI)

**Angiogenesis**
- Angiogenesis and/or vasculogenesis
- Endothelial cells
- Hypoxia/Hypoxia-inducible Factors (HIF-1)
- Lymphatics and/or lymphangiogenesis
- VEGF and/or receptor
- Von Hippel-Lindau (VHL)
KEYWORDS BY TOPIC

**Cell death and apoptosis**
- Apoptosis
- Autophagy
- bcl2 family
- Caspases
- Fas and/or FasL
- Inhibitor of apoptosis proteins (IAPs)
- Mitochondria
- Non apoptotic cell death
- p53, p63, p73
- Senescence
- TRAIL

**Clinical topics**
- Cachexia
- Computer Tomography (CT Scan)
- Diagnosis
- Drug toxicity
- Endocrinology
- GVHD and/or Graft versus Tumor
- Hemostasis and thrombosis
- Magnetic resonance imaging (MRI)
- Metastasis
- Minimal Residual Disease (MRD)
- Nuclear medicine
- Palliative care
- Patient risk stratification
- Pathology
- PET and/or PET-CT
- Prognosis
- Retrospective studies
- Side effects
- SPECT
- Staging
- Survival analysis
- Ultrasound
- Transplantation
Genes, proteins and miscellanea

ATM pathway
ATR pathway
BCR-Abl/Abl
Bone morphogenetic protein (BMP)
BRAF/RAF kinases
BRCA
Embryonic development
Endocytosis
Endoplasmic reticulum (ER)
Epigenetics
Epithelial mesenchyme transition (EMT)
Exosomes and/or endogenous microvesicles
Fatty acids
FGF and/or receptor
Glucocorticoids and/or receptors
Glucose metabolism and/or Warburg effect
Glycoproteins and/or glycosylation
Golgi
Heat shock proteins (HSP)
High Mobility Group Proteins (HMG)
Ion channels
Lipidic mediators
Lipid metabolism
Lipoxygenases
Liver development and/or regeneration
MDM2
Membrane biology
Microbiome
Myc
Netrin receptors

Nitric oxide
Oncogenes
p21 - activated kinases (PAK)
Phosphatases
Phospholipids
Poly-ADP-ribose polymerase (PARP)
Proteasome
RNA binding proteins
Stress response
SUMO and/or sumoylation
Telomere and/or telomerase
Topoisomerase
Ubiquitin and/or ubiquitination
Wilms’ Tumor Gene (WT1)
KEYWORDS BY TOPIC

**Genetics**
- Aneuploidy
- Cancer evolution
- Centrosome
- Chromatin remodeling
- Cytogenetics and/or chromosome alterations
- DNA damage
- DNA double strand break repair (DSBR)
- DNA methylation
- DNA recombination
- DNA repair
- DNA replication
- DNA single strand break repair (SSBR)
- Functional genomics
- Fusion genes
- Gene alteration/gain or loss
- Gene expression and/or profile
- Gene regulation
- Genetics
- Genome wide screening/GWAS
- Genomic imprinting
- Genomic/Genetic instability
- Genomics
- Hereditary DNA repair disorders
- Histone modifications
- Homologous recombination
- Loss of heterozygosity (LOH)
- microRNA
- Mitosis
- mRNA processing
- mRNA translation
- Mutation (somatic and/or germline)

**Nuclear structures**
- Pharmacogenetics/Pharmacogenomics
- Polymorphisms/SNPs
- Post-translational modification
- RNA splicing
- siRNA and/or non coding RNA
- Synthetic lethality
- Transcription
- Transcription factors
- Transformation assays
- Translesion synthesis
- Translocation
- Tumor suppressor genes
KEYWORDS BY TOPIC

**Immunology**
- Autoimmunity/Autoantibodies
- B cells
- Chemokines
- Costimulatory molecules
- COX2
- Cytokines/Interleukins
- Cytotoxic T Lymphocytes (CTL)
- Dendritic cells
- Granulocytes
- Hematopoiesis
- HLA/Major Histocompatibility Complex (MHC)
- Immune escape
- Immunization
- Immuno-editing
- Immunosuppression and/or suppressor cells
- Infection
- Inflammation and/or inflammatory cytokines
- Innate immunity
- Interferons
- Lymphocyte differentiation
- Macrophages and/or monocytes
- Monoclonal antibodies (mAbs) and/or immunoconjugates
- NF-kB family
- NK and/or NKT cells
- Phagocytes and/or phagocytosis
- Prostaglandins
- T cells/TCR
- T helpers
- TNF and/or receptors
- Tolerance

- Toll-like receptors (TLR)
- Treg cells
- Tumor antigen
- Tumor dormancy
- Tumor-Infiltrating Lymphocytes (TIL)
- Vaccine
**Methods**

Animal models  
Biochemistry  
Bioinformatics  
Biomolecular modelling  
Biophysics  
C. elegans  
Chemistry  
Comparative genomics hybridization (CGH)  
Computational biology  
Crystallography  
Docking  
Drosophila  
Epidemiology  
Flow cytometry  
Fluorescence imaging system  
Fluorescence in situ hybridization (FISH)  
Fluorescence resonance energy transfer (FRET)  
Functional validation of target genes  
Immunohistochemistry  
In vitro imaging and/or live cell imaging  
In vivo imaging  
Mass spectrometry  
Mathematical modeling  
Mathematical oncology  
Microarrays  
Microscopy  
Mouse models  
Nanotechnology/Nanoparticles  
Next generation sequencing  
NMR spectroscopy  
Phage display  
Photodynamic therapy and photodetection  
Photonics  
Protein microarrays  
Proteomics  
Spheroids/3D cultures  
Statistics  
Systems biology  
Tissue microarrays (TMA)  
Transgenic mice  
Xenopus  
Yeast  
Zebrfish

**Risk factors**

Aging and cancer  
Biomarkers  
Body mass index (BMI) and/or obesity  
Carcinogenesis  
Diet  
Genotoxicity  
Metabolism/Metabolomics  
Organic compounds  
Oxidative stress and/or Reactive Oxygen Species (ROS)  
Precancerous lesions  
Prevention and/or chemoprevention  
Risk factors  
Screening  
Smoking
KEYWORDS BY TOPIC

**Signaling and cell cycle**
- Androgen and/or receptors
- Cell cycle
- Cell cycle checkpoint G1/S
- Cell cycle checkpoint G2/M
- Cell differentiation and/or differentiation therapy
- Cell signaling
- Crosstalk
- Cyclic AMP
- Cyclins and/or inhibitors
- Cytokinesis
- EGF and/or receptors
- Estrogens and/or receptors
- Folate and/or receptor
- G-proteins and/or GPCR
- Growth factors and/or receptors
- Growth induction and/or growth arrest
- Hedgehog pathway
- HER1-2-3-4
- Hippo pathway
- Hormones
- Insulin
- Insulin-like growth factor (IGF) and/or receptors
- Jak/Stat pathway
- Kinase/Kinome
- MAP Kinases
- MET/HGF
- Notch pathway
- Nuclear receptor
- PDGF and/or receptors
- Peroxisome proliferator-activated receptor (PPAR)
- Phosphorylation
- PI3K/Akt/PTEN/mTOR pathway
- RAS/RAS inhibitors
- Rb/Rb family
- RET
- Retinoic acid and/or receptors
- Rho GTPases family
- Src family
- TGF and/or receptors
- Thyroid hormone
- Tyrosine kinase receptors (TKR) and/or inhibitors
- Wnt/Beta-catenin pathway

**Stem cells**
- Cancer stem cells
- CD133/Stem cell markers
- Circulating tumor cells
- Hematopoietic stem cells
- Normal stem cells
Types of tumors

Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Bladder tumor
Bone disease
Brain and/or nervous system tumors
Breast ca.
Burkitt lymphoma
Cervix or endometrial ca.
Chronic Lymphocytic Leukemia (CLL)
Chronic Myeloid Leukemia (CML)
Colorectal and/or Intestinal ca.
Gastric ca.
Glioma and/or glioblastoma
Gynecological tumors
Head and neck ca.
Hematologic malignancies
Hepatocellular carcinoma (HCC)
Hereditary tumors
Hodgkin's lymphoma
Kidney ca.
Leukaemia
Lung ca.
Lymphomas
Medulloblastoma
Melanoma
Mesothelioma
Myeloma
Neuroblastoma
Neuroendocrine tumors
Non melanoma skin tumors
Osteosarcoma
Ovarian ca.
Pancreas ca.
Pediatric tumors
Prostate ca.
Retinoblastoma
Sarcoma

Therapies

Adjuvant therapy
Anti-angiogenic therapy
Antibody/mAb therapy
Aromatase and/or inhibitors
Chemoimmunotherapy
Chemotherapy and/or chemotherapeutic drugs
Clinical practice guidelines
Clinical trials
Combination therapy
Drug delivery
Drug discovery and/or development
Drug response and/or resistance
Drug screening
Gene therapy
Immunotherapy
Metallo-drugs
Multidrug resistance (MDR)
Peptides as drugs
Pharmacokinetics
Pharmacology
Preclinical studies
Radionuclide therapy
Radiosensitivity and/or resistance
Radiotherapy
Radiotoxicity
Response and/or resistance to therapy
Signal transduction inhibitors
Small molecule inhibitors
Surgery
Target therapy
KEYWORDS BY TOPIC

Viruses
Adenovirus
AIDS/HIV/Kaposi
Epstein-Barr Virus (EBV)
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Herpes virus
Human Papilloma Virus (HPV)
Lentivirus
Oncogenic virus/Viral oncology
Virology